Lantheus Holdings, Inc. (LNTH) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - Specialty & Generic secteur d'activité. Le siège social de l'entreprise est situé à Bedford, MA, United States. Le PDG actuel est Mary Anne Heino.
LNTH a date d'introduction en bourse 2015-06-25, 808 employés à temps plein, cotée sur le NASDAQ Global Market, une capitalisation boursière de $5.39B.
Lantheus Holdings, Inc. is a diagnostic and therapeutic company that develops, manufactures, and commercializes imaging and treatment products for heart disease, cancer, and other conditions worldwide. The company offers a comprehensive portfolio including DEFINITY for cardiac ultrasound enhancement, nuclear medicine generators and radiopharmaceuticals for diagnostic imaging, and therapeutic agents such as AZEDRA for radiotherapy and PYLARIFY for prostate cancer detection. Lantheus also markets RELISTOR for opioid-induced constipation and maintains a pipeline of investigational products including flurpiridaz F-18 for cardiac blood flow assessment and PSMA-targeted radiotherapeutics. The company serves hospitals, clinics, integrated delivery networks, and radio pharmacies through strategic partnerships with leading healthcare and pharmaceutical companies including GE Healthcare, Bayer, and Regeneron Pharmaceuticals. Founded in 1956 and headquartered in North Billerica, Massachusetts, Lantheus is a established player in nuclear medicine and molecular imaging.
